Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral
therapy. N Engl J Med.1997;337:734-739.
Gulick RM, Mellors JW, Havlir D.
et al. Simultaneous vs
sequential initiation of therapy with indinavir, zidovudine, and
lamivudine for HIV-1 infection: 100 week follow-up. JAMA.1998;280:35-41.
Montaner JSG, Reiss P, Cooper D.
et al. A
randomized, double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA.1998;279:930-937.
Fischl M, Greenberg S, Clumeck N.
et al. Safety and
activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral
naïve subjects.In: Program and abstracts of the 12th World AIDS
Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract
127/12230.
Staszewski S, Morales-Ramirez J, Flanigan T.
et al. A
phase II, multicenter, randomized, open-label study to compare the
antiretroviral activity and tolerability of efavirenz (EFV) + indinavir
(IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV +
ZDV + 3TC at 24 weeks [DMP 266-006].In: Program and
abstracts of the 12th World AIDS Conference; June 28-July 3, 1998;
Geneva, Switzerland. Abstract 22336.
Renaud M, Ait HM, Katlama C.
et al. Dynamics of
CD4+ T cell recovery in a large cohort treated with highly
active antiretroviral therapy at advanced stages of HIV disease.In:
Program and abstracts of the 12th World AIDS Conference; June 28-July
3, 1998; Geneva, Switzerland. Abstract 41179.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled
trial of two nucleoside analogues plus indinavir in persons with human
immunodeficiency virus infection and CD4 cell counts of 200 per cubic
millimeter or less. N Engl J Med.1997;337:725-733.
Hogg RS, Heath KV, Yip B.
et al. Improved survival
among HIV-infected individuals following initiation of antiretroviral
therapy. JAMA.1998;279:450-454.
Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining
morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Raboud JM, Montaner JSG, Conway B.
et al. Suppression
of plasma viral load below 20 copies/mL is required to achieve a
long-term response to therapy. AIDS.1998;12:1619-1624.
Montaner JSG, Raboud JM, Rae S.for the INCAS and
AVANTI Study Groups. Adherence to treatment increases duration of
virologic suppression regardless of pVL nadir.In: Program and
abstracts of the 38th Interscience Conference on Antimicrobial Agents
and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract
LB-10.
Carpenter CCJ, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1998: updated
recommendations of the International AIDS Society–USA Panel. JAMA.1998;280:78-86.
Carr A, Samaras K, Burton S.
et al. A syndrome of
peripheral lipodystrophy, hyperlipidaemia and insulin resistance in
patients receiving HIV protease inhibitors. AIDS.1998;12:F51-F58.
Carr A, Samaras K, Chisholm DJ, Cooper DA.Pathogenesis
of HIV-1-protease inhibitor-associated peripheral lipodystrophy,
hyperlipidaemia, and insulin resistance. Lancet.1998;351:1881-1883.
Wong JK, Hezareh M, Gunthard HF.
et al. Recovery of
replication-competent HIV despite prolonged suppression of plasma
viremia. Science.1997;278:1291-1295.
Finzi D, Hermankova M, Pierson T.
et al. Identification of a reservoir for HIV-1 in patients on highly active
antiretroviral therapy. Science.1997;278:1295-1300.
Chun TW, Stuyver L, Mizell SB.
et al. Presence of an
inducible HIV-1 latent reservoir during highly active antiretroviral
therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.
Montaner JSG, Harris M, Mo T, Harrigan PR.Rebound of
plasma HIV viral load following prolonged suppression with combination
therapy. AIDS.1998;12:1398-1399.
Montaner JSG, Hogg R, Raboud J, Harrigan R, O′Shaughnessy M.Antiretroviral treatment in 1998. Lancet.1998;352:1919-1922.
Cooper DA, Emery S.Therapeutic strategies for HIV
infection: time to think hard. N Engl J Med.1998;339:1319-1321.
Hall DB, Montaner JSG, Reiss P.
et al. Induction-maintenance antiretroviral therapy: proof of concept. AIDS.1998;12:F41-F44.
Reijers MH, Weverling GJ, Jurriaans S.
et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected
individuals: Amsterdam Duration of Antiretroviral Medication (ADAM)
study. Lancet.1998;352:185-190.
Havlir DV, Marschner IC, Hirsch MS.
et al. Maintenance
antiretroviral therapies in HIV-infected subjects with undetectable
plasma HIV RNA after triple-drug therapy. N Engl J Med.1998;339:1261-1268.
Pialoux G, Raffi F, Brun-Vezinet F.
et al. A randomized
trial of three maintenance regimens given after three months of
induction therapy with zidovudine, lamivudine, and indinavir in
previously untreated HIV-1–infected patients. N Engl J Med.1998;339:1269-1276.